行情

ZYNE

ZYNE

Zynerba Pharms
NASDAQ

实时行情|Nasdaq Last Sale

3.470
+0.060
+1.76%
盘后: 3.500 +0.03 +0.86% 17:54 04/02 EDT
开盘
3.400
昨收
3.410
最高
3.550
最低
3.270
成交量
21.93万
成交额
--
52周最高
16.47
52周最低
2.550
市值
8,173.99万
市盈率(TTM)
-2.2838
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ZYNE价格均价为15.71,最高价位26.00,最低价为4.500。

EPS

ZYNE 新闻

更多
  • Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know
  • Zacks · 1小时前
  • 外盘头条:短短两周 美国抹掉金融危机来近半就业增长
  • 新浪美股 · 2小时前
  • 多家美媒称美政府将发表声明 要求疫情热点地区民众佩戴布制口罩
  • 央视 · 3小时前
  • 失业金申领飙升 纽约州失业保险信托基金接近破产
  • 新浪美股 · 3小时前

所属板块

生物技术和医学研究
+2.53%
制药与医学研究
+2.50%

热门股票

代码
价格
涨跌幅

ZYNE 简况

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
展开

微牛提供Zynerba Pharmaceuticals Inc(NASDAQ-ZYNE)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ZYNE股票新闻,以帮助您做出投资决策。